First Trust Advisors
FPRX

First Trust Advisors’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

First Trust Advisors’s Portfolio FPRX Stock Details FPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-22,577
Closed -$816K – 2482
2017
Q1 		$816K Sell
22,577
-19,028
-46% -$839K ﹤0.01% 1921
2016
Q4 		$2.08M Buy
41,605
+4,519
+12% +$237K 0.01% 1427
2016
Q3 		$1.95M Sell
37,086
-4,164
-10% -$199K 0.01% 1348
2016
Q2 		$1.71M Buy
+41,250
New +$1.79M 0.01% 1382

Other funds holding FPRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

First Trust Advisors's FPRX Position: Q2 2017 in Review

First Trust Advisors sold out of Five Prime Therapeutics, Inc. (FPRX) in Q2 2017, closing a stake of 22,577 shares — an estimated $816K sold.

First Trust Advisors first reported a position in FPRX in Q2 2016 and held it in 4 quarters. The position peaked at $2.08M in Q4 2016. 123 funds tracked by Wall St. Rank hold FPRX as of Q2 2017.

  • First Trust Advisors reported no remaining Five Prime Therapeutics, Inc. position as of Q2 2017 after selling out during the quarter.
  • First Trust Advisors sold 22,577 Five Prime Therapeutics, Inc. shares in Q2 2017, an estimated $816K.
  • First Trust Advisors first reported a position in Five Prime Therapeutics, Inc. in Q2 2016 and held it in 4 quarters.
  • First Trust Advisors's Five Prime Therapeutics, Inc. position peaked at $2.08M in Q4 2016.
  • 123 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q2 2017.

Based on First Trust Advisors's 13F filing for Q2 2017, filed 2 Aug 2017.